• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Vyant Bio Inc. (Amendment)

    2/7/22 4:39:54 PM ET
    $VYNT
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $VYNT alert in real time by email
    SC 13G/A 1 sc13ga110022002_02072022.htm

     UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

    SCHEDULE 13G

    (Rule 13d-102)

    INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT

    TO RULES 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED

    PURSUANT TO RULE 13d-2(b)

    (Amendment No. 1)1

     

    Vyant Bio, Inc. f/k/a Cancer Genetics, Inc.

     (Name of Issuer)

    Common Stock, par value $0.0001 per share

     (Title of Class of Securities)

    92942V109

     (CUSIP Number)

    December 31, 2021

     (Date of Event Which Requires Filing of this Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

       ☐  Rule 13d-1(b)

       ☒  Rule 13d-1(c)

       ☐  Rule 13d-1(d)

     

     

     

    1              The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

    The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

    CUSIP No. 92942V109

     

      1   NAME OF REPORTING PERSON  
             
            Bigger Capital Fund, LP  
      2   CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) ☒
            (b) ☐
               
      3   SEC USE ONLY    
               
                 
      4   CITIZENSHIP OR PLACE OF ORGANIZATION  
             
            Delaware  
    NUMBER OF   5   SOLE VOTING POWER  
    SHARES          
    BENEFICIALLY         0  
    OWNED BY   6   SHARED VOTING POWER  
    EACH          
    REPORTING         0  
    PERSON WITH   7   SOLE DISPOSITIVE POWER  
             
              0  
        8   SHARED DISPOSITIVE POWER  
               
              0  
      9   AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON  
             
            0  
      10   CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES     ☐
           
               
      11   PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)  
             
            0%  
      12   TYPE OF REPORTING PERSON  
             
            PN  

      

    2

    CUSIP No. 92942V109

      1   NAME OF REPORTING PERSON  
             
            Bigger Capital Fund GP, LLC  
      2   CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) ☒
            (b) ☐
               
      3   SEC USE ONLY    
               
                 
      4   CITIZENSHIP OR PLACE OF ORGANIZATION  
             
            Delaware  
    NUMBER OF   5   SOLE VOTING POWER  
    SHARES          
    BENEFICIALLY         0  
    OWNED BY   6   SHARED VOTING POWER  
    EACH          
    REPORTING         0  
    PERSON WITH   7   SOLE DISPOSITIVE POWER  
             
              0  
        8   SHARED DISPOSITIVE POWER  
               
              0  
      9   AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON  
             
            0  
      10   CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES     ☐
           
               
      11   PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)  
             
            0  
      12   TYPE OF REPORTING PERSON  
             
            OO  

      

    3

    CUSIP No. 92942V109

     

      1   NAME OF REPORTING PERSON  
             
            District 2 Capital Fund LP  
      2   CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) ☒
            (b) ☐
               
      3   SEC USE ONLY    
               
                 
      4   CITIZENSHIP OR PLACE OF ORGANIZATION  
             
            Delaware  
    NUMBER OF   5   SOLE VOTING POWER  
    SHARES          
    BENEFICIALLY         0  
    OWNED BY   6   SHARED VOTING POWER  
    EACH          
    REPORTING         244,828 shares of Common Stock issuable upon exercise of Warrants  
    PERSON WITH   7   SOLE DISPOSITIVE POWER  
             
              0  
        8   SHARED DISPOSITIVE POWER  
               
              244,828 shares of Common Stock issuable upon exercise of Warrants  
      9   AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON  
             
            244,828 shares of Common Stock issuable upon exercise of Warrants  
      10   CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES     ☐
           
               
      11   PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)  
             
            Less than one percent  
      12   TYPE OF REPORTING PERSON  
             
            PN  

      

    4

    CUSIP No. 92942V109

     

      1   NAME OF REPORTING PERSON  
             
            District 2 Capital LP  
      2   CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) ☒
            (b) ☐
               
      3   SEC USE ONLY    
               
                 
      4   CITIZENSHIP OR PLACE OF ORGANIZATION  
             
            Delaware  
    NUMBER OF   5   SOLE VOTING POWER  
    SHARES          
    BENEFICIALLY         0  
    OWNED BY   6   SHARED VOTING POWER  
    EACH          
    REPORTING         244,828 shares of Common Stock issuable upon exercise of Warrants  
    PERSON WITH   7   SOLE DISPOSITIVE POWER  
             
              0  
        8   SHARED DISPOSITIVE POWER  
               
              244,828 shares of Common Stock issuable upon exercise of Warrants  
      9   AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON  
             
            244,828 shares of Common Stock issuable upon exercise of Warrants  
      10   CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES     ☐
           
               
      11   PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)  
             
            Less than one percent  
      12   TYPE OF REPORTING PERSON  
             
            PN  

      

    5

    CUSIP No. 92942V109

     

      1   NAME OF REPORTING PERSON  
             
            District 2 GP LLC  
      2   CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) ☒
            (b) ☐
               
      3   SEC USE ONLY    
               
                 
      4   CITIZENSHIP OR PLACE OF ORGANIZATION  
             
            Delaware  
    NUMBER OF   5   SOLE VOTING POWER  
    SHARES          
    BENEFICIALLY         0  
    OWNED BY   6   SHARED VOTING POWER  
    EACH          
    REPORTING         244,828 shares of Common Stock issuable upon exercise of Warrants  
    PERSON WITH   7   SOLE DISPOSITIVE POWER  
             
              0  
        8   SHARED DISPOSITIVE POWER  
               
              244,828 shares of Common Stock issuable upon exercise of Warrants  
      9   AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON  
             
            244,828 shares of Common Stock issuable upon exercise of Warrants  
      10   CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES     ☐
           
               
      11   PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)  
             
            Less than one percent  
      12   TYPE OF REPORTING PERSON  
             
            OO  

      

    6

    CUSIP No. 92942V109

     

      1   NAME OF REPORTING PERSON  
             
            District 2 Holdings LLC  
      2   CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) ☒
            (b) ☐
               
      3   SEC USE ONLY    
               
                 
      4   CITIZENSHIP OR PLACE OF ORGANIZATION  
             
            Delaware  
    NUMBER OF   5   SOLE VOTING POWER  
    SHARES          
    BENEFICIALLY         0  
    OWNED BY   6   SHARED VOTING POWER  
    EACH          
    REPORTING         244,828 shares of Common Stock issuable upon exercise of Warrants  
    PERSON WITH   7   SOLE DISPOSITIVE POWER  
             
              0  
        8   SHARED DISPOSITIVE POWER  
               
              244,828 shares of Common Stock issuable upon exercise of Warrants  
      9   AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON  
             
            244,828 shares of Common Stock issuable upon exercise of Warrants  
      10   CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES     ☐
           
               
      11   PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)  
             
            Less than one percent  
      12   TYPE OF REPORTING PERSON  
             
            OO  

      

    7

    CUSIP No. 92942V109

     

      1   NAME OF REPORTING PERSON  
             
            Michael Bigger  
      2   CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) ☒
            (b) ☐
               
      3   SEC USE ONLY    
               
                 
      4   CITIZENSHIP OR PLACE OF ORGANIZATION  
             
            USA  
    NUMBER OF   5   SOLE VOTING POWER  
    SHARES          
    BENEFICIALLY         0  
    OWNED BY   6   SHARED VOTING POWER  
    EACH          
    REPORTING         244,828 shares of Common Stock issuable upon exercise of Warrants*  
    PERSON WITH   7   SOLE DISPOSITIVE POWER  
             
              0  
        8   SHARED DISPOSITIVE POWER  
               
              244,828 shares of Common Stock issuable upon exercise of Warrants*  
      9   AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON  
             
            244,828 shares of Common Stock issuable upon exercise of Warrants*  
      10   CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES     ☐
           
               
      11   PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)  
             
            Less than one percent  
      12   TYPE OF REPORTING PERSON  
             
            IN  

    *Consists of 244,828 shares of Common Stock issuable issuable upon exercise of Warrants owned by District 2 CF.

      

    8

    CUSIP No. 92942V109

    Item 1(a).Name of Issuer:

    Vyant Bio, Inc. f/k/a Cancer Genetics, Inc., a Delaware corporation (the “Issuer”).

    Item 1(b).Address of Issuer’s Principal Executive Offices:

    2 Executive Campus
    2370 State Route 70
    Suite 310
    Cherry Hill, NJ 08002

     

    Item 2(a).Name of Person Filing
    Item 2(b).Address of Principal Business Office or, if None, Residence
    Item 2(c).Citizenship

    Bigger Capital Fund, LP (“Bigger Capital”)

    2250 Red Springs Drive
    Las Vegas, NV 89135

    Citizenship: Delaware

     

    Bigger Capital Fund GP, LLC (“Bigger GP”)

    2250 Red Springs Drive
    Las Vegas, NV 89135

    Citizenship: Delaware

     

    District 2 Capital Fund LP (“District 2 CF”)

    175 W. Carver Street

    Huntington, NY 11743

    Citizenship: Delaware

     

    District 2 Capital LP (“District 2”)

    175 W. Carver Street

    Huntington, NY 11743

    Citizenship: Delaware

     

    District 2 GP LLC (“District 2 GP”)

    175 W. Carver Street

    Huntington, NY 11743

    Citizenship: Delaware

     

    District 2 Holdings LLC (“District 2 Holdings”)

    175 W. Carver Street

    Huntington, NY 11743

    Citizenship: Delaware

     

    Michael Bigger

    2250 Red Springs Drive
    Las Vegas, NV 89135

    Citizenship: USA 

    9

    CUSIP No. 92942V109

    Each of the foregoing is referred to as a “Reporting Person” and collectively as the “Reporting Persons.”

    Item 2(d).Title of Class of Securities:

    Common Stock, $0.0001 par value (the “Common Stock”).

    Item 2(e).CUSIP Number:

    92942V109

    Item 3.If This Statement is Filed Pursuant to Rule 13d-1(b), or 13d-2(b) or (c), Check Whether the Person Filing is a:
        /x/ Not applicable.
           
      (a) / / Broker or dealer registered under Section 15 of the Exchange Act.
           
      (b) / / Bank as defined in Section 3(a)(6) of the Exchange Act.
           
      (c) / / Insurance company as defined in Section 3(a)(19) of the Exchange Act.
           
      (d) / / Investment company registered under Section 8 of the Investment Company Act.
           
      (e) / / An investment adviser in accordance with Rule 13d-1(b)(1)(ii)(E).
           
      (f) / / An employee benefit plan or endowment fund in accordance with Rule 13d-1(b)(1)(ii)(F).
           
      (g) / / A parent holding company or control person in accordance with Rule 13d-1(b)(1)(ii)(G).
           
      (h) / / A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act.
           
      (i) / / A church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act.
           
      (j) / / A non-U.S. institution in accordance with Rule 13d-1(b)(1)(ii)(J).  
           
      (k) / / Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
           
          If filing as a non-U.S. institution in accordance with Rule 240.13d-1(b)(1)(ii)(J), please specify the type of institution: ____

     

    Item 4.Ownership
    (a)Amount beneficially owned:
    10

    CUSIP No. 92942V109

    As of December 31, 2021, Bigger Capital and Bigger GP did not beneficially own any Common Stock.

    As of December 31, 2021, District 2 CF beneficially owned 244,828 shares of Common Stock issuable upon exercise of Warrants.

    District 2, as the investment manager of District 2 CF, may be deemed to beneficially own the 244,828 shares of Common Stock issuable upon exercise of the Warrants beneficially owned by District 2 CF.

    District 2 GP, as the general partner of District 2 CF, may be deemed to beneficially own 244,828 shares of Common Stock issuable upon exercise of the Warrants beneficially owned by District 2 CF.

    District 2 Holdings, as the managing member of District 2 GP, may be deemed to beneficially own the 244,828 shares of Common Stock issuable upon exercise of the Warrants beneficially owned by District 2 CF.

    Mr. Bigger, as the managing member of District 2 Holdings, may be deemed to beneficially own the 244,828 shares of Common Stock issuable upon exercise of Warrants owned by District 2 CF.

    The foregoing should not be construed in and of itself as an admission by any Reporting Person as to beneficial ownership of any shares of Common Stock owned by another Reporting Person. Each of District 2, District 2 GP, District 2 Holdings and Mr. Bigger disclaims beneficial ownership of the shares of Common Stock beneficially owned by District 2 CF. The filing of this statement shall not be construed as an admission that any such person or entity is the beneficial owner of any such securities.

    (b)Percent of class:

    The following percentages are based on 28,989,623 shares of Common Stock outstanding as of November 9, 2021 as reported in the Issuer’s Form 10-Q for the period ended September 30, 2021 filed on November 12, 2021.

    As of the close of business on December 31, 2021, each of District 2 CF, District 2, District 2 GP and District 2 Holdings and Mr. Bigger may be deemed to beneficially own less than 1% of the outstanding shares of Common Stock.

    (c)Number of shares as to which such person has:
    (i)Sole power to vote or to direct the vote

    See Cover Pages Items 5-9.

    (ii)Shared power to vote or to direct the vote

    See Cover Pages Items 5-9.

    (iii)Sole power to dispose or to direct the disposition of

    See Cover Pages Items 5-9.

    11

    CUSIP No. 92942V109

    (iv)Shared power to dispose or to direct the disposition of

    See Cover Pages Items 5-9.

    Item 5.Ownership of Five Percent or Less of a Class.

    If this statement is being filed to report the fact that as of the date hereof, the Reporting Person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following: [X].

    Item 6.Ownership of More than Five Percent on Behalf of Another Person.

    District 2, District 2 GP, District 2 Holdings and Mr. Bigger may be deemed to share voting and dispositive power over the shares of Common Stock beneficially owned by District 2 CF.

    Item 7.Identification and Classification of the Subsidiary That Acquired the Security Being Reported on by the Parent Holding Company or Control Person.

    Not Applicable.

    Item 8.Identification and Classification of Members of the Group.

    See Exhibit 99.1. Previously Filed.

    Item 9.Notice of Dissolution of Group.

    Not Applicable.

    Item 10.Certifications.

    By signing below each of the undersigned certifies that, to the best of its knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

    12

    CUSIP No. 92942V109

    SIGNATURE

    After reasonable inquiry and to the best of his knowledge and belief, each of the undersigned certifies that the information set forth in this statement is true, complete and correct.

    Dated: February 7, 2022

    Bigger Capital Fund, LP   Bigger Capital Fund GP, LLC
         
    By: Bigger Capital Fund GP, LLC, its general partner   By:

    /s/ Michael Bigger

            Michael Bigger
    By:

    /s/ Michael Bigger

        Managing Member
      Michael Bigger      
      Managing Member      
          District 2 Capital LP
             
    District 2 Capital Fund LP   By:

    /s/ Michael Bigger

            Michael Bigger
    By: District 2 GP LLC, its general partner     Managing Member
             
    By:

    /s/ Michael Bigger

         
      Michael Bigger   District 2 Holdings LLC
      Managing Member      
          By:

    /s/ Michael Bigger

            Michael Bigger
    District 2 GP LLC     Managing Member
             
    By:

    /s/ Michael Bigger

         
      Michael Bigger  

    /s/ Michael Bigger

      Managing Member   Michael Bigger
    13

     

    Get the next $VYNT alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $VYNT

    DatePrice TargetRatingAnalyst
    3/8/2022$5.00 → $4.00Buy
    HC Wainwright & Co.
    10/6/2021$5.00Buy
    HC Wainwright & Co.
    More analyst ratings

    $VYNT
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Vyant Bio Provides Update on Winddown Activities

    CHERRY HILL, N.J., Dec. 26, 2023 (GLOBE NEWSWIRE) -- Vyant Bio, Inc. ("Vyant Bio" or "Company") (OTC:VYNT) is providing an update to shareholders regarding its winddown activities pursuant to its Plan of Liquidation and Dissolution following the sale of substantially all of its assets. Vyant Bio's Board of Directors has filed its Certificate of Dissolution with the State of Delaware with an effective time of 5:00 p.m. on December 29, 2023, after which the Company's stock will cease trading on the OTC, and the holders of shares of the Company's common stock will cease to have any rights in respect of that stock, except the right of holders at such time to receive distributions, if any, purs

    12/26/23 9:15:00 AM ET
    $VYNT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Vyant Bio Provides Update on Winddown Activities

    CHERRY HILL, N.J., Nov. 10, 2023 (GLOBE NEWSWIRE) -- Vyant Bio, Inc. ("Vyant Bio" or "Company") (OTC:VYNT) is providing an update to shareholders regarding its winddown activities pursuant to its Plan of Liquidation and Dissolution following the sale of substantially all of its assets. Vyant Bio's Board of Directors currently anticipates that it will file a Certificate of Dissolution with the State of Delaware in late December 2023, after which the Company's common stock will cease to trade and holders of shares of the Company's common stock will cease to have any rights in respect of that stock, except the right of holders at the date we file the Certificate of Dissolution to receive dist

    11/10/23 4:05:00 PM ET
    $VYNT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Vyant Bio Announces Stockholder Approval of Plan of Dissolution

    CHERRY HILL, N.J., Nov. 01, 2023 (GLOBE NEWSWIRE) -- Vyant Bio, Inc. ("Vyant Bio" or "Company") (OTC:VYNT) is announcing the results of its special meeting of stockholders on November 1, 2023 (the "Special Meeting"). At the Special Meeting, Vyant Bio's stockholders, upon the unanimous recommendation of Vyant Bio's board of directors, voted in favor of the proposal to approve the voluntary liquidation and dissolution of the Company, pursuant to a Plan of Liquidation and Dissolution (the "Dissolution Proposal). The proposal received the affirmative vote of holders of 94.0% of the shares casting votes and 53.1% of the Company's total outstanding common shares. Vyant Bio's Board will determin

    11/1/23 11:45:00 AM ET
    $VYNT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $VYNT
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    HC Wainwright & Co. reiterated coverage on Vyant Bio with a new price target

    HC Wainwright & Co. reiterated coverage of Vyant Bio with a rating of Buy and set a new price target of $4.00 from $5.00 previously

    3/8/22 6:21:03 AM ET
    $VYNT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    HC Wainwright & Co. initiated coverage on Vyant Bio with a new price target

    HC Wainwright & Co. initiated coverage of Vyant Bio with a rating of Buy and set a new price target of $5.00

    10/6/21 7:13:38 AM ET
    $VYNT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $VYNT
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4: Hansen Paul R. transferred by will 6,783 shares), increasing direct ownership by 4% to 159,778 units

    4 - Vyant Bio, Inc. (0001349929) (Issuer)

    2/27/23 5:41:18 PM ET
    $VYNT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4: Hansen Paul R. was granted 4,032 shares, increasing direct ownership by 3% to 152,995 units

    4 - Vyant Bio, Inc. (0001349929) (Issuer)

    1/19/23 4:30:40 PM ET
    $VYNT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4: Harris Geoffrey E. was granted 5,712 shares, increasing direct ownership by 41% to 19,761 units

    4 - Vyant Bio, Inc. (0001349929) (Issuer)

    1/19/23 4:30:27 PM ET
    $VYNT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $VYNT
    SEC Filings

    View All

    SEC Form PRE 14A filed by Vyant Bio Inc.

    PRE 14A - Vyant Bio, Inc. (0001349929) (Filer)

    7/31/23 5:15:27 PM ET
    $VYNT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 15-12G filed by Vyant Bio Inc.

    15-12G - Vyant Bio, Inc. (0001349929) (Filer)

    5/15/23 8:00:19 AM ET
    $VYNT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Vyant Bio Inc. filed SEC Form 8-K: Leadership Update

    8-K - Vyant Bio, Inc. (0001349929) (Filer)

    5/10/23 8:30:11 AM ET
    $VYNT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $VYNT
    Leadership Updates

    Live Leadership Updates

    View All

    Vyant Bio Announces Robert T. Fremeau, Jr. Ph.D. as Chief Scientific Officer

    Cherry Hill, N.J., Oct. 26, 2021 (GLOBE NEWSWIRE) -- Vyant Bio, Inc. ("Vyant Bio", "Company") (NASDAQ:VYNT), an emerging global drug discovery company identifying small and large molecule therapeutics to treat central nervous system (CNS) and oncology-related diseases, announced today the appointment of Robert T. Fremeau Jr., Ph.D., as Chief Scientific Officer. Dr. Fremeau is an experienced R&D leader with over two decades of drug discovery experience in academia and industry advancing next-gen drug development for severe neurological disorders. He is an accomplished scientist and biotech entrepreneur with an established history of scientific innovation and program leadership at the int

    10/26/21 8:00:00 AM ET
    $VYNT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $VYNT
    Financials

    Live finance-specific insights

    View All

    Vyant Bio Reports Third Quarter 2022 Results and Provides Strategic and Business Highlights

    Q3 2022 and Recent Scientific and Business Highlights Completed the sale of its vivoPharm subsidiary to Reaction Biology Corporation for $5.5 million in an upfront cash paymentDelivered platform and poster presentations at the 2022 CDKL5 Forum hosted by the Loulou FoundationEntered into a master services agreement and related statement of work with an Australian CRO in November 2022 to support the Company's adult Rett Syndrome clinical trialProgress with licensing our iPSC technology to transition key product sales customers Q3 2022 Financial Highlights $9.4 million of cash and equivalents as of September 30, 2022Current cash balances, net proceeds from the sale of

    11/15/22 8:00:00 AM ET
    $VYNT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Reaction Biology and Vyant Bio Announce Closing of Definitive Agreement to Acquire U.S. Operations of Vyant Bio, Inc. Subsidiary

    ~ Reaction Biology Acquires the Hershey, Pennsylvania-Based U.S. Operations of Vyant Bio Subsidiary vivoPharm PTY Ltd. ~ ~ Transaction Expands Reaction Biology's Capabilities to Provide Customers with Solutions in Both the Discovery and Development of New Drug Candidates ~ ~ Transaction Provides Vyant Bio with Additional Capital to Deploy into Further Development of its Therapeutic Pipeline in Genetic CNS Disorders ~ MALVERN, PA and CHERRY HILL, NJ, Nov. 03, 2022 (GLOBE NEWSWIRE) -- Reaction Biology Corporation ("Reaction"), an industry-leading provider of drug discovery services, and Vyant Bio, Inc. ("Vyant Bio") (NASDAQ:VYNT), an innovative biotechnology company reinventing drug

    11/3/22 9:10:00 AM ET
    $VYNT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Vyant Bio Reports Second Quarter and First Half 2022 Results and Provides Strategic and Business Highlights

    Conference Call and Webcast Today at 4:30 pm ET Scientific and Business Highlights Based on preclinical efficacy data in our human Rett cortical organoid model, we are advancing VYNT0126 into clinical trials in Rett patients with encouragement and guidance from the International Rett Syndrome FoundationContinued progress with efforts towards the divestiture of the vivoPharm businessProgress with licensing our iPSC technology to transition key product sales customers Financial Highlights $11.7 million of cash and equivalents as of June 30, 2022Cash runway approximately 18 months CHERRY HILL, N.J., Aug. 22, 2022 (GLOBE NEWSWIRE) -- Vyant Bio, Inc. ("Vyant Bio" or "Company") (N

    8/22/22 4:10:00 PM ET
    $VYNT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $VYNT
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by Vyant Bio Inc. (Amendment)

    SC 13G/A - Vyant Bio, Inc. (0001349929) (Subject)

    2/14/23 8:30:50 AM ET
    $VYNT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Vyant Bio Inc.

    SC 13G - Vyant Bio, Inc. (0001349929) (Subject)

    2/14/22 1:04:16 PM ET
    $VYNT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Vyant Bio Inc. (Amendment)

    SC 13G/A - Vyant Bio, Inc. (0001349929) (Subject)

    2/11/22 7:36:40 AM ET
    $VYNT
    Biotechnology: Pharmaceutical Preparations
    Health Care